XyloCor is a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease.
XyloCor is dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
XyloCor was co-founded in 2013 by Ronald Crystal, and Todd Rosengart. The company is headquartered in Malvern, Pennsylvania.
XyloCor's lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XC001 deposits the gene for vascular endothelial growth factor (VEGF) in targeted heart cells.
XyloCor also has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks.
XyloCor is backed by Fountain Healthcare Partners, Sofinnova Investments, LSP, Longwood Fund, Lumira Ventures and others. The company completed an oversubscribed $39.6M Series A on Mar 22, 2021.